Search PubMed⌕ Search

PubMed · 9822874

Predicting improved function after myocardial revascularization.

Abstract

The distinction of left ventricular (LV) dysfunction caused by fibrosis from that arising from viable (hibernating and/or stunned) myocardium has important implications for the management of patients with ischemic cardiomyopathy. In many of these patients, LV function can improve significantly after revascularization. Using positron emission tomography (PET), increased glucose uptake in dysfunctional segments with reduced blood flow at rest (PET mismatch) indicates presence of viable myocardium, whereas a concordant reduction in blood flow and glucose uptake (PET match) reflects myocardial scar. The average positive and negative predictive accuracies of PET for predicting improved function after revascularization are 76% and 82%, respectively. The greater the number of viable myocardial segments, the greater is the probability that revascularization will improve global LV function and, consequently, improve heart failure symptoms and survival. Early revascularization affords a more complete recovery of LV function. In patients with PET mismatch, early referral to revascularization improves long-term survival over medical therapy, regardless of symptoms. In patients without PET mismatch, long-term survival is similar with medical therapy or revascularization especially if minimal or no anginal symptoms are present. Noninvasive evaluation of myocardial viability should be an important component of the diagnostic evaluation of patients with heart failure due to coronary artery disease. This approach will likely enhance the selection of patients with poor cardiac function in whom revascularization will likely improve both the quality and quantity of life.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M F Di Carli. 1998. Predicting improved function after myocardial revascularization.. https://doi.org/10.1097/00001573-199811000-00006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The bidirectional genetic causality between immunocyte phenotypes and dilated cardiomyopathy: A bidirectional Mendelian randomization study.

The association between immunocyte phenotypes and dilated cardiomyopathy (DCM) has been explored, however the exact pathogenesis of the relationship between immune cells and DCM is unclear. This bidirectional two-sample Mendelian randomization (MR) research aims to further validate the causal link between 731 immunocyte phenotypes and DCM. Summary statistics from a genome-wide association study data of individuals with European ancestry were utilized, including 1444 DCM cases and 353,937 controls, as well as 3757 European adults for the 731 immunocyte phenotypes. Causal effects were estimated using inverse variance weighted, MR-Egger regression, weight median estimator, weighted mode, and simple mode. Sensitivity analysis was conducted to confirm data robustness and feasibility. Based on the inverse variance weighted findings, 14 immunocyte phenotypes were risk factors for DCM (P&#x2005;<&#x2005;.05, odds ratio [OR]&#x2005;>&#x2005;1), while 15 immunocyte phenotypes exhibited a protective effect on DCM (P&#x2005;<&#x2005;.05, OR&#x2005;<&#x2005;1). The results of reverse MR analysis suggested evidence that DCM occurrence might elevate the levels of 17 immunocyte phenotypes (P&#x2005;<&#x2005;.05, OR&#x2005;>&#x2005;1) and decrease the levels of 9 immunocyte phenotypes (P&#x2005;<&#x2005;.05, OR&#x2005;<&#x2005;1). Our research indicated that CD28 on secreting regulatory T cell could mitigate the occurrence of DCM, and reciprocally, the progression of DCM could reduce the level of CD28 on secreting regulatory T cell. This study confirmed the bidirectional genetic predictive relationship between immunocyte phenotypes and DCM, underscoring the complex interplay between DCM and the immune system.

Cardiomyopathy, Dilated↗

Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy.

OBJECTIVE: Dilated cardiomyopathy is characterized by elevated arterial vascular resistance and impaired nitric oxide (NO)-dependent vasodilation. Insulin-like growth factor-I (IGF-I) has been shown to stimulate endothelial NO-synthase resulting in endothelium-dependent vasodilation. Growth hormone (GH) substitution therapy leads in GH-deficient patients to significant increases of IGF-I which may alter systemic vascular resistance by stimulating NO production. This study was designed to evaluate the effects of treatment with recombinant human growth hormone (GH) on NO production and NO-dependent vascular effects in patients with dilated cardiomyopathy. METHODS: 50 patients with dilated cardiomyopathy were randomly assigned to double-blind treatment with 2 I.U. of GH or placebo for 3 months. Central hemodynamics were determined by Swan-Ganz catheter and cardiac output was obtained by the thermodilution method. Serum GH and IGF-I levels were measured and systemic NO production was determined from urinary nitrate and cyclic GMP excretion rates in 42 patients. RESULTS: GH treatment caused in comparison to the placebo group a significant increase of IGF-I by 91 ng/ml (P = 0.0001). Urinary excretion rates of nitrate and cyclic GMP increased also significantly by 38 mumol/mmol creatinine (P = 0.027) and 65 nmol/mmol creatinine (P = 0.003), respectively. The parallel increase of both marker molecules indicates increased systemic NO production during GH treatment. CONCLUSION: GH treatment induces a significant, but moderate increase of systemic NO production in patients with dilated cardiomyopathy. This effect may be mediated by IGF-I stimulating endothelial NO synthase.

Cardiomyopathy, Dilated↗